THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in China Traditional Chinese Medicine Holdings Co. Limited, you should at once hand this circular and the accompanying form of proxy to the purchaser or to the transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 570)

PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the annual general meeting (the "**AGM**") of China Traditional Chinese Medicine Holdings Co. Limited (the "**Company**") to be held at Conference Room, 4th Floor, Winteam Plaza, 6 Kuiqi Second Road, Chancheng District, Foshan City, Guangdong Province, China, on Friday, 26 June 2026 at 2:30 p.m. is set out on pages 14 to 15 of this circular. A form of proxy for use at the AGM is also enclosed. Such form of proxy is also published on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk and the website of the Company at www.china-tcm.com.cn.

If you do not intend or are unable to attend the AGM and wish to appoint a proxy/proxies to attend and to speak and vote on your behalf, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event not later than 48 hours before the time appointed for the holding of the AGM (i.e. before 2:30 p.m. on Wednesday, 24 June 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting at the AGM or any adjourned meeting should you so wish and in such event, the form of proxy will be deemed to be so revoked.

1 June 2026

CONTENTS

Pages

Definitions 1

Letter from the Board 3

1. Introduction 3
2. Proposed Re-election of Directors 4
3. Proposed Re-appointment of Auditor 5
4. Annual General Meeting 5
5. Actions to be Taken 6
6. Closure of the Register of Members 6
7. Voting by Way of Poll 6
8. Recommendation 6
9. Responsibility Statement 7

Appendix I – Details of Directors Proposed for Re-election 8

Notice of Annual General Meeting 14

In this circular, the following expressions have the following meanings unless the context requires otherwise:

"AGM"	means the annual general meeting of the Company to be held at Conference Room, 4th Floor, Winteam Plaza, 6 Kuiqi Second Road, Chancheng District, Foshan City, Guangdong Province, China, on Friday, 26 June 2026 at 2:30 p.m., or any adjournment thereof
"AGM Notice"	means the notice convening the AGM as set out on pages 14 to 15 of this circular
"Articles of Association"	means the articles of association of the Company, as amended or supplemented from time to time
"BDO"	means BDO Limited, the auditor proposed to be re-appointed by the Company at the AGM
"Board"	means the board of Directors
"CNPGC"	means China National Pharmaceutical Group Co., Ltd. (中國醫藥集團有限公司), a state-owned enterprise established in the PRC
"Company"	means China Traditional Chinese Medicine Holdings Co. Limited (中國中藥控股有限公司), a company incorporated in Hong Kong with limited liability and the Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 570)
"Corporate Governance Code"	means the Corporate Governance Code contained in Appendix C1 to the Listing Rules
"Director(s)"	means the director(s) of the Company
"Group"	means the Company and its subsidiaries
"HK$"	means Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	means the Hong Kong Special Administrative Region of the PRC
"Latest Practicable Date"	means 26 May 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information for inclusion in this circular
"Listing Rules"	means the Rules Governing the Listing of Securities on the Stock Exchange

"Nomination Committee"	means the nomination committee of the Board
"PRC"	means the People's Republic of China, and for the purpose of this circular only excluding Hong Kong, the Macau Special Administrative Region and Taiwan
"RMB"	means Renminbi, the lawful currency of the PRC
"SFO"	means the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended or supplemented from time to time
"Share(s)"	means share(s) of the Company
"Shareholder(s)"	means holder(s) of the Share(s)
"Stock Exchange"	means The Stock Exchange of Hong Kong Limited
"TCM"	means traditional Chinese medicine



CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

Executive Directors:
Mr. YANG Jun *(Chairman)*
Mr. LI Hongjian
Mr. PENG Li

Non-Executive Directors:
Mr. LI Xiangrong
Mr. ZU Jing
Ms. XU Jinghui
Mr. CHEN Kun
Mr. HUANG Hao

Independent Non-Executive Directors:
Mr. XIE Rong
Mr. YU Tze Shan Hailson
Mr. QIN Ling
Mr. LI Weidong

Registered Office:
Room 1601
Emperor Group Centre
288 Hennessy Road
Wanchai
Hong Kong

1 June 2026

To the Shareholders

Dear Sir or Madam,

PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to give you notice of the AGM and the information relating to, inter alia, the proposals for (i) the re-election of Directors; and (ii) the re-appointment of auditor of the Company.

2. PROPOSED RE-ELECTION OF DIRECTORS

The Board currently comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui, Mr. CHEN Kun and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.

Pursuant to the Article 92 of the Articles of Association, Mr. PENG Li and Mr. CHEN Kun shall hold office only until the first annual general meeting of the Company after their appointment and shall then be eligible for re-election.

Pursuant to Article 101 of the Articles of Association, Mr. LI Xiangrong, Mr. ZU Jing, Mr. XIE Rong and Mr. LI Weidong will retire by rotation at the AGM. The retiring Directors, being eligible, offer themselves for re-election.

The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution of the Directors and the independence of all independent non-executive Directors with reference to the nomination principles and criteria set out in the board diversity policy and director nomination policy. The Nomination Committee has recommended to the Board on re-election of all the above-mentioned Directors including the aforesaid independent non-executive Directors who are due to retire at the AGM.

The independent non-executive Directors, Mr. XIE Rong and Mr. LI Weidong, who have offered themselves for re-election at the AGM, have demonstrated their abilities to provide an independent view to the Company's matters during their years of appointment. The Nomination Committee has reviewed the independence of Mr. XIE Rong and Mr. LI Weidong and has formed the view that each of them has met the independence guidelines set out in Rule 3.13 of the Listing Rules and is independent in accordance with the terms of the guidelines, taking into account, among others, their abilities to exercise independent judgment in relation to the Company's affairs by scrutinising and monitoring the operation of the Board during their tenure of office. In addition, the Board is of the view that they have provided valuable contributions to the Company and have demonstrated their abilities to provide independent, balanced and objective views on the Company's affairs. The Board is satisfied that notwithstanding that Mr. XIE Rong would have served as an independent non-executive Director for more than nine years as of the Latest Practicable Date (if his re-election is approved by the Shareholders at the AGM), his independence is not affected by his tenure with the Company and his professional knowledge and business experience will continue to offer valuable contributions to the Board, the Company and the Shareholders as a whole.

In proposing Mr. XIE Rong and Mr. LI Weidong to be re-elected as independent non-executive Directors at the AGM, the Board has considered, among other things, the valuable business experience, knowledge and professionalism of Mr. XIE Rong and Mr. LI Weidong, as further described in Appendix I to this circular.

With their unique background, the Board considers that Mr. XIE Rong and Mr. LI Weidong to be highly valued and respected members of the Board, and can contribute to the diversity of the Board, in particular, with Mr. XIE Rong's strong educational background and professional experience in his expertise, including his in-depth knowledge in pharmaceutical industry, accounting, financial affairs, audit, compliance and regulation and with Mr. LI Weidong's law major background and in-depth knowledge in compliance operations of listed company.

Therefore, the Board is of the view that the re-election of Mr. XIE Rong and Mr. LI Weidong as independent non-executive Directors is in the interest of the Company and the Shareholders as a whole and recommends their re-election at the AGM.

In compliance with the requirements of code provisions B.2.3 and F.1.2 of the Corporate Governance Code, a separate resolution will be proposed at the AGM for the re-election of each individual director whether such Director is an executive Director, a non-executive Director or an independent non-executive Director.

Brief biographical details of the Directors who are proposed to be re-elected at the AGM are set out in Appendix I to this circular.

3. PROPOSED RE-APPOINTMENT OF AUDITOR

BDO will retire as the auditor of the Company at the AGM and, being eligible, offer itself for re-appointment. The Board proposed to re-appoint BDO as the auditor of the Company for the year ending 31 December 2026 and hold the office until the conclusion of the next annual general meeting of the Company, and it was proposed to authorise the Board to determine its remuneration.

The estimated audit fee payable to BDO for the audit of the consolidated financial statements of the Group for the year ending 31 December 2026 is expected to be RMB3,200,000. Such fee has been determined after due consideration and arm's length negotiations between the Company and BDO, taking into account, among other things, the size, nature and complexity of the Group's business operations, the expected scope of the audit, the audit timetable, and the required auditor resources. The estimated audit fee also assumes that there will be no material change in the Group's operations, accounting policies or regulatory environment during the year, and that the Company will provide timely and adequate assistance and information as reasonably required for the purposes of the audit.

Unless there is a material change in the basis or assumptions set out above, the final audit fee should not deviate materially from the above estimated amount. In the event of any material change, the Company will make further disclosure as appropriate.

4. ANNUAL GENERAL MEETING

The AGM Notice is set out on pages 14 to 15 of this circular to consider and approve the resolutions relating to, inter alia, the re-election of Directors and the re-appointment of auditor of the Company.

5. ACTIONS TO BE TAKEN

A form of proxy for use at the AGM is enclosed with this circular and such form of proxy is also published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.china-tcm.com.cn. If you do not intend or are unable to attend the AGM and wish to appoint a proxy/proxies to attend and to speak and vote on your behalf, you are requested to complete the form of proxy and return it to the share registrar of the Company in accordance with the instructions printed thereon not less than 48 hours before the time fixed for holding the AGM (i.e. before 2:30 p.m. on Wednesday, 24 June 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting at the AGM if you so wish.

6. CLOSURE OF THE REGISTER OF MEMBERS

To ascertain the Shareholders' entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, 23 June 2026 to Friday, 26 June 2026, both days inclusive, during which period no transfer of Shares will be registered. The Shareholders whose names appear on the register of members of the Company on Friday, 26 June 2026 are entitled to attend and vote at the AGM. In order to be eligible to attend and vote at the AGM, all duly completed transfer forms accompanied by the relevant share certificates must be lodged with the share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, 22 June 2026.

7. VOTING BY WAY OF POLL

Pursuant to Rule 13.39(4) of the Listing Rules, all votes at the AGM will be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules.

8. RECOMMENDATION

The Directors believe that the re-election of Directors and the re-appointment of auditor of the Company are in the interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

9. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

Yours faithfully,
By order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

The biographical details of six Directors proposed to be re-elected at the AGM are set out as follows:

Mr. PENG Li, aged 54, was appointed to the Board of Directors on 25 July 2025. Mr. PENG graduated from rehabilitation medicine major of Tongji Medical College of Huazhong University of Science and Technology with a doctoral degree and is qualified as a Chief Physician and doctoral tutor.

Mr. PENG has extensive experience in clinical practice, scientific research and hospital management with a deep focus on traditional Chinese medicine. During his medical career, he actively promoted the development of TCM disciplines and worked and exchanged at Hamburg Trauma Hospital in Germany. Mr. PENG previously served as physician, director, deputy secretary of the Party Committee and vice president of the acupuncture department of Shiyan Taihe Hospital (Affiliated Hospital of Hubei University of Medicine), secretary of the Party Committee and director of Shiyan Hospital of Traditional Chinese Medicine; and secretary of the Party Committee, director and level I division rank official of Shiyan Health Commission. Mr. PENG has joined China National Pharmaceutical Group Co., Ltd. since February 2024, and served as executive dean of Sinopharm Medical Innovation Research Institute, chairman and secretary of the Party Committee of Sinopharm Central China (Hubei) Healthcare Co., Ltd., and secretary of the Party Committee of Sinopharm Dongfeng General Hospital. Mr. PENG currently also serves as deputy secretary of the Party Committee and chairman of the Labor Union of the Company.

Save as disclosed above, Mr. PENG has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. PENG does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. PENG does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. PENG entered into an employment agreement with the Company commencing from 25 July 2025, which shall automatically be effective hereafter. Mr. PENG is subject to retirement by rotation and re-election at the annual general meeting of the Company and vacation of office in accordance with the Articles of Association. Mr. PENG is entitled to receive director's fee, basic salary, discretionary bonuses or other benefits based on his performances and duties, profitability of the Group and the prevailing market condition. For the year ended 31 December 2025, the aggregate remuneration of Mr. PENG as the executive Director was RMB514,000.

Save as disclosed above, Mr. PENG is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. PENG required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

Mr. LI Xiangrong, aged 56, was appointed to the Board on 15 January 2025. Mr. LI holds a bachelor's degree and master's degree of science of Peking University, with qualification of lectureship, and he is a member of Pharmaceutical Intellectual Property Research Professional Committee of Chinese Pharmaceutical Association.

Mr. LI possesses diversified experience spanning academia, public administration and corporate governance. He worked at Peking University from July 1995 to July 2001, and served as a member of the party leadership group and vice mayor of Jinggangshan Municipal People's Government, Jiangxi Province from June 1997 to August 1998. Mr. LI has joined China National Pharmaceutical Group Co., Ltd. since October 2003. He previously served as deputy manager of the asset management department and manager of the planning & development department of China National Biotec Group Company Limited, as well as deputy director of the planning & development department and director of the board office of China National Pharmaceutical Group Co., Ltd. From February 2018 to November 2024, he was vice president and company secretary of China National Biotec Group Company Limited, during which he concurrently served as a director of Beijing Tiantan Biological Products Corporation Limited (600161.SH) from October 2018 to May 2023. Mr. LI has been serving as a full-time external director of China National Pharmaceutical Group Co., Ltd. since October 2024. Mr. LI currently also serves as a non-executive director of Chongqing Taiji Industry (Group) Co., Ltd. (600129.SH, since March 2025).

Save as disclosed above, Mr. LI has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. LI does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. LI does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. LI entered into an appointment letter with the Company commencing from 15 January 2025, for an initial term of three years. Mr. LI is subject to retirement by rotation and re-election at the annual general meeting of the Company and vacation of office in accordance with the Articles of Association. The Director's fee of Mr. LI would be determined and paid by CNPGC with reference to his responsibilities scope, performance and prevailing market condition. It is expected that he will not receive any Director's fee from the Company.

Save as disclosed above, Mr. LI is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. LI required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

Mr. ZU Jing, aged 55, was appointed to the Board on 15 January 2025. Mr. ZU holds a bachelor's degree of economics of Beijing Economics College, with the qualification of senior accountant.

Mr. ZU has more than thirty years of experience in financial management and corporate general management. Mr. ZU previously served as deputy general manager of the finance department of China National Service Corporation for Chinese Personnel Working Aboard and deputy general manager & chief financial officer of Zhongfu Jiayuan Trade Company (中服嘉遠貿易公司); general manager of the finance department, deputy chief financial officer and chief financial officer of China Sinopharm International Company (currently known as China Sinopharm International Corporation); and chief financial officer of Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SH). From April 2022 to March 2024, he was director of the international cooperation department of China National Pharmaceutical Group Co., Ltd. Mr. Zu has

been serving as a full-time external director of China National Pharmaceutical Group Co., Ltd. since October 2024. Mr. ZU currently also serves as a non-executive director of Sinopharm Group Co., Ltd. (01099.HK, since February 2025).

Save as disclosed above, Mr. ZU has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. ZU does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. ZU does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. ZU entered into an appointment letter with the Company commencing from 15 January 2025, for an initial term of three years. Mr. ZU is subject to retirement by rotation and re-election at the annual general meeting of the Company and vacation of office in accordance with the Articles of Association. The Director's fee of Mr. ZU would be determined and paid by CNPGC with reference to his responsibilities scope, performance and prevailing market condition. It is expected that he will not receive any Director's fee from the Company.

Save as disclosed above, Mr. ZU is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. ZU required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

Mr. CHEN Kun, aged 54, was appointed to the Board on 15 May 2026. Mr. CHEN obtained bachelor of laws degree from Chinese people's Liberation Army University of International Relations in July 1994, and held qualification of engineer.

Mr. CHEN has a diverse professional background, having served as deputy director of the First Analysis Division at the China Anti-Money Laundering Monitoring and Analysis Center of the People's Bank of China, and as director (division head) of the Eighth Discipline Inspection and Supervision Office of the Discipline Inspection and Supervision Group of the Central Commission for Discipline Inspection and the National Commission of Supervision stationed at the State-owned Assets Supervision and Administration Commission of the State Council. Mr. CHEN joined CNPGC in November 2019, where he served as deputy secretary of the Discipline Inspection Committee. From February 2021 to December 2025, he served as secretary of the Discipline Inspection Committee and a member of the Party Committee of China National Biotec Group Company Limited. Mr. CHEN has served as a full-time external director of CNPGC since December 2025.

Save as disclosed above, Mr. CHEN has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. CHEN does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. CHEN does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. CHEN entered into an appointment letter with the Company commencing from 15 May 2026, for an initial term of three years. Mr. CHEN is subject to retirement by rotation and re-election at the annual general meeting of the Company and vacation of office in accordance with the Articles of Association. The Director's fee of Mr. CHEN would be determined and paid by CNPGC with reference to his responsibilities scope, performance and prevailing market condition. It is expected that he will not receive any Director's fee from the Company.

Save as disclosed above, Mr. CHEN is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. CHEN required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

Mr. XIE Rong, aged 73, was appointed to the Board on 5 February 2013. Mr. XIE obtained a doctoral degree in economics, majoring in accounting in Shanghai University of Finance and Economics, in January 1993. He has over fifty years of profound academic accumulation and professional practical experience.

From September 1994 to November 1997, Mr. XIE served as deputy head of the accounting department at Shanghai University of Finance and Economics. From December 1997 to October 2002, he was a partner at KPMG Huazhen Certified Public Accountants (Shanghai). From October 2002 to November 2017, he successively served as professor and vice president of Shanghai National Accounting Institute, making outstanding contributions to accounting education, research and professional talent development. Mr. XIE has extensive experience in the governance of listed companies. He has served as an independent nonexecutive director of a number of listed companies in Hong Kong and Mainland China, covering various sectors including finance, transportation, industry, pharmaceuticals, public utilities and consumer goods. His former directorships include (without limitation): independent non-executive director of SAIC Motor Corporation Limited (600104.SH); COSCO Shipping Energy Transportation Co., Ltd. (01138.HK, 600026.SH), China Eastern Airlines Corporation Limited (00670.HK, 600115.SH), China CITIC Bank Corporation Limited (00998.HK, 601998.SH), Tianjin Capital Environmental Protection Group Company Limited (01065.HK, 600874.SH), Sinopharm Group Co., Ltd. (01099.HK); Shanghai Baosight Software Co., Ltd. (600845.SH), China Everbright Bank Company Limited (06818.HK, 601818.SH); Shenwan Hongyuan Group Co., Ltd. (06806.HK, 000166.SZ), Shanghai Bairun Investment Holding Group Co., Ltd. (002568.SZ); and Baoshan Iron & Steel Co., Ltd. (600019.SH). Mr. XIE currently also serves as an independent non-executive director of Shanghai Foreign Service Holding Group Co., Ltd. (600662.SH, since September 2021).

Save as disclosed above, Mr. XIE has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. XIE does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. XIE does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. XIE entered into an appointment letter with the Company for an initial term of three years commencing from 5 February 2013. He accepted and signed a renewed appointment letter with the Company on 5 February 2025, with a term of three years. Mr. XIE is subject to retirement by rotation and re-election at the annual general meeting of the Company and vacation of office in accordance with the Articles of Association. Mr. XIE is entitled to receive director's fee, basic salary, discretionary bonuses or other benefits based on his performances and duties, profitability of the Group and the prevailing market condition. For the year ended 31 December 2025, Mr. XIE has received a director's fee of HK$250,000 and the special allowance of HK$60,000 for attending board meeting in person.

Save as disclosed above, Mr. XIE is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. XIE required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

Mr. LI Weidong, aged 57, was appointed to the Board on 18 February 2019. Mr. LI obtained dual bachelor's degrees in science and law from Nanjing University in 1992, and a doctor of juridical science degree from City University of Hong Kong in 2004. He is qualified to practice as a lawyer in both Hong Kong and Mainland China.

Mr. LI has long specialized in cross-border legal matters and capital markets legal services. From September 1992 to April 1997, he served as a full-time lawyer at Nanjing Zhongshan Law Firm and Jiangsu Jingwei Law Firm. He is currently Director of Hip Shing Law Firm (Shenzhen, Hong Kong), and has extensive influence in legal practice across the Guangdong-Hong Kong-Macao Greater Bay Area. Mr. LI has rich experience in listed company governance. Mr. LI was an independent non-executive director of Ocean Line Port Development Limited (8502.HK) from June 2018 to July 2024 and an independent director of LUFAX Holding, Ltd. (LU.NYSE, 06623.HK) from April 2018 to August 2025. He currently serves as an independent non-executive director of a number of Hong Kong and Mainland listed companies, including: independent non-executive director of Hualin Securities Co., Ltd. (002945.SZ, since June 2025), Shenzhen Yitoa Intelligent Control Co., Ltd. (300131.SZ, since November 2023) and Shenzhen Yantian Port Holdings Co., Ltd. (000088.SZ, since July 2022).

Save as disclosed above, Mr. LI has not held directorship in other listed companies in the past three years or any other positions with the Company and other members of the Group, and has not held any other major appointments and professional qualifications.

As at the Latest Practicable Date, Mr. LI does not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. LI does not have any relationship with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company.

Mr. LI entered into an appointment letter with the Company for an initial term of three years commencing from 18 February 2019. He accepted and signed a renewed appointment letter with the Company on 18 February 2025, with a term of three years. Mr. LI is subject to retirement by rotation and re-election at the

annual general meeting of the Company and vacation of office in accordance with the Articles of Association. Mr. LI is entitled to receive director's fee, basic salary, discretionary bonuses or other benefits based on his performances and duties, profitability of the Group and the prevailing market condition. For the year ended 31 December 2025, Mr. LI has received a director's fee of HK$250,000 and the special allowance of HK$60,000 for attending board meeting in person.

Save as disclosed above, Mr. LI is not aware of any other matters that need to be brought to the attention of the Shareholders in relation to his re-election as a Director and any other information in relation to Mr. LI required to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.



CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the annual general meeting (the "**AGM**") of China Traditional Chinese Medicine Holdings Co. Limited (the "**Company**") will be held at Conference Room, 4th Floor, Winteam Plaza, 6 Kuiqi Second Road, Chancheng District, Foshan City, Guangdong Province, China, on Friday, 26 June 2026 at 2:30 p.m. for the following purposes. Unless the context otherwise requires, the terms used herein shall have the same meaning as those defined in the circular of the Company dated 1 June 2026 (the "**Circular**"):

ORDINARY RESOLUTIONS

1. To receive and consider the audited financial statements, the report of the directors and the independent auditor's report of the Company for the year ended 31 December 2025.

2. (a) Each as a separate resolution, to re-elect the following retiring directors of the Company (the "**Director**"):

   (i) to re-elect Mr. PENG Li as a Director;

   (ii) to re-elect Mr. LI Xiangrong as a Director;

   (iii) to re-elect Mr. ZU Jing as a Director;

   (iv) to re-elect Mr. CHEN Kun as a Director;

   (v) to re-elect Mr. XIE Rong as a Director; and

   (vi) to re-elect Mr. LI Weidong as a Director.

   (b) To authorize the board of directors of the Company (the "**Board**") to fix the Directors' remuneration.

3. To re-appoint BDO Limited as the auditor of the Company and authorize the Board to fix its remuneration.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 1 June 2026

Notes:

1. Any member entitled to attend and vote at the AGM is entitled to appoint one or more proxies to exercise all or any of his/her rights to attend, speak and vote instead of him/her, provided that the proxy is appointed to represent respectively the number of Shares held by the Shareholder as specified in the relevant instrument of appointment. A proxy need not be a shareholder of the Company.

2. In order to be valid, the form of proxy together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power or authority, must be deposited at the Company's share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not less than 48 hours before the time appointed for holding the meeting (i.e. before 2:30 p.m. on Wednesday, 24 June 2026) or any adjournment thereof.

3. To ascertain the Shareholders' entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, 23 June 2026 to Friday, 26 June 2026, both days inclusive, during which period no transfer of Shares will be registered. The Shareholders whose names appear on the register of members of the Company on Friday, 26 June 2026 are entitled to attend and vote at the AGM. In order to be eligible to attend and vote at the AGM, all duly completed transfer forms accompanied by the relevant share certificates must be lodged with the share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, 22 June 2026.

4. Pursuant to Rule 13.39(4) of the Listing Rules, all votes at the meeting will be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules.

5. With regard to items 2 to 3 set out in the notice, the Circular giving details of the proposed re-election of Directors and the proposed re-appointment of the Company's auditor will be sent to the Shareholders on 1 June 2026. The biographical details of the Directors who are proposed to be re-elected are set out in Appendix I to the Circular. The existing auditor, BDO Limited, will retire as the auditor of the Company with effect from the conclusion of the AGM and will seek re-appointment.

6. As at the date of this notice, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui, Mr. CHEN Kun and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.